Policy & Regulation
Roche releases eight-year positive data for multiple sclerosis drug OCREVUS(R) (ocrelizumab)
14 October 2021 -

Roche (SIX: RO, ROG; OTCQX: RHHBY), a Switzerland-based pharmaceutical company, announced on Wednesday new long-term data that it said reinforce the benefit of early initiation and ongoing treatment of OCREVUS(R) (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations.

The company stated that OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine response in patients treated with OCREVUS. These data are being presented virtually at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

'Many neurologists have had first-hand experience with OCREVUS over eight years in clinical trials and witnessed the consistently favourable efficacy and safety outcomes in RMS and PPMS, especially the reductions in progression to disability when given early in the disease,' said Levi Garraway, M.D., Ph.D. Roche's chief medical officer and head of Global Product Development. 'Additionally, the new safety analysis of the shorter two-hour OCREVUS infusion is encouraging particularly for groups that are often underrepresented in clinical trials. We continue our commitment to diversity and health equity in clinical trial participation and access to treatment.'



Related Headlines